

A

Docket # PF-0148-2 DIV



"Express Mail" mailing label number EL315813786 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on October 8, 1999

By: Nancy RamosPrinted: Nancy Ramos

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No.09/134,593 , filed on August 13, 1998, entitled NOVEL HUMAN PYROPHOSPHATASE, which is a divisional of issued patent no. 5,843,665, Serial No.08/741,437, filed on October 31, 1996 , entitled HUMAN PYROPHOSPHATASE.

1. X Enclosed is a copy of the prior application, U. S. Application Serial No.08/741,437 filed October 31, 1996, including the oath or declaration as originally signed.
2. X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the computer readable form of the "Sequence Listing" for the instant divisional application is identical with that filed for Serial No. 08/741,437, filed October 31, 1996, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. 08/741,437 as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. X Cancel in this application original claims 2-16 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. X The inventor(s) of the invention being claimed in this application is (are): Phillip R. Hawkins and Jennifer L. Hillman.

5. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's/applicants' signature(s) as filed on January 6, 1997 is enclosed.
6. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 08/741,437, filed October 31, 1996, which is a divisional of U.S. patent no. 5,843,665, U.S. serial no. 09/134,593, filed August 13, 1998."
7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate	Basic Fee
					\$760.00
Total Claims	3	-20	0	x \$18	\$0
Indep. Claims	1	-3	0	x \$78	\$0
<u> </u> Multiple Dependent Claim(s), if any + \$260					\$0

TOTAL FILING FEE \$ 0

8. An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. X Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$ 760.00
The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

Duplicate copies of these papers are enclosed.

10. X New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on January 16, 1997, at reel 8437, frame 0115.
12. X A preliminary amendment is enclosed.
13. X Also enclosed Information Disclosure Statement (2 pp., in duplicate); and List of References Cited PTO-1449 (1 p.); copy of previously submitted Revocation and Power of Attorney (2 pp.).

14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

- a. An associate power of attorney is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE PHARMACEUTICALS, INC.
PATENT DEPARTMENT
3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555, Fax: (650) 849-8886

Date: 08 October 1999

By:



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

- Inventor(s)
- Assignee of complete interest
- X Attorney or agent of record
- Filed under 37 CFR 1.34(a)
- Registration number if acting under 37 CFR 1.34(a) _____.

"Express Mail" mailing label number EL315813786 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on October 8, 1999

By: Nancy Ramos

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: A NOVEL HUMAN PYROPHOSPHATASE

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

IN THE SPECIFICATION

Please amend the application as follows:

At page 2, line 29, delete "Figure 1 shows" and insert --Figures 1A, 1B, 1C and 1D show--.

At page 2, line 30, delete "MacDNASIS PRO™" and insert --MACDNASIS PRO™--.

At page 3, line 2, delete "Figure 2 shows" and insert --Figures 2A and 2B show--.

At page 3, line 7, delete "MacDNASIS PRO" and insert --MACDNASIS PRO™--.

At page 3, line 12, delete "LIFESEQ FL™" and insert --LIFESEQ FL®--.

At page 4, line 1, delete "herein" (second instance).

At page 11, line 1, delete "Fig. 1" and insert ---Figures 1A, 1B, 1C and 1D--.

At page 11, line 4, after "NO:5", insert --)--.

At page 11, line 25, delete "Fig. 1" and insert --Figures 1A, 1B, 1C and 1D--.

At page 13, line 17, delete "Sequenase®" and insert --SEQUENASE®--.

At page 14, line 20, delete "PromoterFinder™" and insert --PROMOTERFINDER™--.

At page 14, line 21, delete "is".

At page 15, line 3, delete "devise" and insert --device--.

At page 15, line 4, delete "Genotyper™" and insert --GENOTYPER™--.

At page 15, line 5, delete "Sequence Navigator™" and insert --SEQUENCE
NAVIGATOR™--.

At page 17, line 16, "Bluescript®" and insert --BLUESCRIPT®--.

At page 17, line 17, "pSport1™" and insert --PSPORT1™--.

At page 17, line 29, "Bluescript®" and insert --BLUESCRIPT®--.

At page 24, line 6, after "used" insert --to--.

At page 38, line 2, delete "an Beckman" and insert --a Beckman--.

At page 38, line 13, delete "pSport1" and insert --PSPORT1™--.

At page 38, line 14, delete "DH5a™" and insert --DH5α™--.

At page 40, line 14, delete "LIFESEQ™" and insert --LIFESEQ®--.

At page 42, line 9, delete "QIAQuick™" and insert --QIAQUICK™--.

At page 44, line 2, delete "Fig. 1" and insert --Figures 1A, 1B, 1C and 1D--.

At page 44, line 4, delete "Fig. 1" and insert --Figures 1A, 1B, 1C and 1D--.

At page 44, line 9, delete "Fig. 1" and insert --Figures 1A, 1B, 1C and 1D--.

IN THE CLAIMS

Please cancel claims 2-16, without prejudice.

REMARKS

No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment. Applicants also note that the number of sheets of drawings has increased to accomodate the Draftspersons objections. The new formal drawings are identical to those originally filed. No new matter has been added.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **This form is enclosed in duplicate.**

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 08 October 1999



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

663001-0459T40

A NOVEL HUMAN PYROPHOSPHATASE

FIELD OF THE INVENTION

This invention relates to nucleic acid and amino acid sequences of a novel inorganic pyrophosphatase and to the use of these sequences in the diagnosis, prevention, and treatment of inflammatory diseases and cancer.

5

BACKGROUND OF THE INVENTION

Inorganic pyrophosphate (PPi) is produced in living cells in numerous metabolic pathways. These include the synthesis of polymers such as DNA, RNA, protein, and polysaccharides as well as small molecules such as cyclic-GMP and cyclic-AMP. PPi is also produced by oxidative phosphorylation and glycolysis. Most of these reactions are readily reversible in the presence of excess PPi, and PPi, itself, inhibits some of the cellular enzymes involved in these metabolic pathways. In order to promote the forward reactions and stabilize the reaction products, it is essential that PPi be removed. The enzyme pyrophosphatase (PPase) makes this energetically favorable hydrolysis of PPi possible.

10

PPase has been studied extensively in yeast and bacteria. Its activity has been shown to be essential for cell viability, and it may be essential for the fidelity of DNA replication as well. PPase is widely distributed in mammalian tissues where its activity varies widely.

Little is known about how PPase activity is regulated in mammals or about the functions of PPase isolated from specific tissues. Multiple isoforms of PPase have, however, been found

15

in humans and a number of other animals, perhaps indicating that there are functionally distinct isoforms of the enzyme in mammals. Bovine retina contains the highest level of PPase activity found in any mammalian tissue, and this enzyme has been sequenced and characterized (Yang, Z and Wensel, TG (1992) J Biol Chem 267: 24634-40, 24641-7).

PPase activity was found to be essential for controlling PPi levels and the synthesis and degradation of cGMP which, in turn, controls the process of phototransduction in these cells.

20

The discovery of polynucleotides encoding pyrophosphatase, and the molecules themselves, presents the opportunity to investigate the role of pyrophosphatase in controlling the various metabolic pathways in cells involving PPi synthesis. The discovery of new pyrophosphatase molecules satisfies a need in the art by providing new diagnostic or therapeutic compositions useful in the treatment of diseases and conditions associated with uncontrolled cell signaling and cell proliferation such as inflammatory diseases and cancer.

SUMMARY OF THE INVENTION

The present invention features a novel human inorganic pyrophosphatase hereinafter designated HPYP and characterized as having similarity to pyrophosphatases from human and other sources.

Accordingly, the invention features a substantially purified HPYP having chemical homology to human, bovine, and yeast pyrophosphatases above and the amino acid sequence, SEQ ID NO:1.

One aspect of the invention features isolated and substantially purified polynucleotides that encode HPYP. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.

The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HPYP. The present invention also features antibodies which bind specifically to HPYP, and pharmaceutical compositions comprising substantially purified HPYP. The invention also features the use of agonists and antagonists of HPYP.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of HPYP. The alignment was produced using MacDNASIS PRO™ software

(Hitachi Software Engineering Co., Ltd., San Bruno, CA).

Figure 2 shows the amino acid sequence alignments among HPYP (SEQ ID NO:1), a partial sequence of the human pyrophosphatase (GI 727225; SEQ ID NO:3), bovine pyrophosphatase (GI 585322; SEQ ID NO:4) and yeast pyrophosphatase (GI 4199; SEQ ID NO:5). The alignment was produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figure 3 shows the hydrophobicity plot (MacDNASIS PRO software) for HPYP, SEQ ID NO: 1; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

Figure 4 shows the hydrophobicity plot for bovine pyrophosphatase, SEQ ID NO:4.

Figure 5 shows the northern analysis for SEQ ID NO:2. The northern analysis was produced electronically using LIFESEQ FL™ database (Incyte Pharmaceuticals, Inc., Palo Alto, CA).

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices,

and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not
5 entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

“Nucleic acid sequence” as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or
10 synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, “amino acid sequence” as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence and fragments or portions thereof, of a naturally occurring or synthetic molecule.

Where “amino acid sequence” is recited herein to refer to an amino acid sequence of a
15 naturally occurring protein molecule, “amino acid sequence” and like terms, such as “polypeptide” or “protein” are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

“Peptide nucleic acid”, as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been
20 added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

HPYP, as used herein, refers to the amino acid sequences of substantially purified HPYP obtained from any species, particularly mammalian, including bovine, ovine, porcine,
25 murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

“Consensus”, as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or which has been
30 assembled from the overlapping sequences of more than one Incyte clone using the

GELVIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both extended and assembled.

A "variant" of HPYP, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

A "deletion", as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HPYP, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which, when bound to HPYP, causes a change in HPYP which modulates the activity of HPYP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HPYP.

The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to HPYP, blocks the biological or immunological activity of HPYP. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HPYP.

The term "modulate", as used herein, refers to a change or an alteration in the biological activity of HPYP. Modulation may be an increase or a decrease in protein activity, a change in binding characteristics, or any other change in the biological, functional or immunological properties of HPYP.

5 The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of HPYP or portions thereof and, as such, is able to effect some or all of the actions of [REF PROT]-like molecules.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding HPYP or the encoded HPYP. Illustrative of such modifications would be
10 replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at
15 least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

"Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR
20 Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen binds between
25 complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid
30 support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed for

in situ hybridization).

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, for the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene

glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length human HPYP and fragments thereof.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome.

They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HPYP or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding HPYP in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NO: 2, as used herein, comprise any alteration in the sequence of polynucleotides encoding HPYP including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this

definition is the detection of alterations to the genomic DNA sequence which encodes HPYP (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2), the inability of a selected fragment of SEQ ID NO: 2 to hybridize to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HPYP (e.g., using fluorescent in situ hybridization [FISH] to metaphase chromosomes spreads).

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant.

Antibodies that bind HPYP polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from translated RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin.

The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

THE INVENTION

The invention is based on the discovery of a novel human pyrophosphatase (HPYP), the polynucleotides encoding HPYP, and the use of these compositions for the diagnosis, prevention, or treatment of inflammatory diseases and cancer.

Nucleic acids encoding the human HPYP of the present invention were first identified in Incyte Clone 768320 from the lung tissue cDNA library LUNGNOTO4 through a computer-generated search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 000769 and 002394/ U937NOT01, 768320/ LUNGNOTO4, 853164/ NGANNOT01, and 1283643/ COLNNOT16.

In one embodiment, the invention encompasses the novel human pyrophosphatase, a

polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Fig. 1. HPYP is 289 amino acids in length and has chemical and structural homology with the partial sequence of a human pyrophosphatase (GI 727225; SEQ ID NO:3), a bovine pyrophosphatase (GI 585322; SEQ ID NO:4) and a yeast pyrophosphatase (GI 4199; SEQ ID NO:5). In particular, HPYP shares 77% identity with the partial human pyrophosphatase sequence (SEQ ID NO:3) over the length of that molecule. The bovine and yeast pyrophosphatases each share 96% and 37% identity with HPYP, respectively. Despite the wide variation in overall sequence identity between these four molecules, all of them contain the seventeen amino acid residues previously identified as being important for enzyme activity in Ppase (Lahti, R et al (1990) Biochim Biophys Acta 1038: 338-345). In particular, the sequence, DEGETDWK, beginning at D(148) is identical for all four molecules. As illustrated by Figs. 3 and 4, HPYP and bovine pyrophosphatase have rather similar hydrophobicity plots. Northern analysis (Fig. 5) shows the expression of this sequence in various libraries, at least 43% of which are immortalized or cancerous and at least 24% of which involve immune response. Of particular note is the expression in thyroid tissue, colon tumor, and rheumatoid arthritis.

The invention also encompasses HPYP variants. A preferred HPYP variant is one having at least 80%, and more preferably 90%, amino acid sequence similarity to the HPYP amino acid sequence (SEQ ID NO:1). A most preferred HPYP variant is one having at least 95% amino acid sequence similarity to SEQ ID NO:1.

The invention also encompasses polynucleotides which encode HPYP. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HPYP can be used to generate recombinant molecules which express HPYP. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid of SEQ ID NO:2 as shown in Fig. 1.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HPYP, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices.

These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HPYP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HPYP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HPYP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HPYP or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HPYP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of a DNA sequence, or portions thereof, which encode HPYP and its derivatives, entirely by synthetic chemistry. After production, the synthetic gene may be inserted into any of the many available DNA vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HPYP or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Kimmel, A.R. (1987; *Methods Enzymol.* Vol. 152), and may be used at a defined stringency.

Altered nucleic acid sequences encoding HPYP which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HPYP. The encoded protein may also contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HPYP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility,

hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of HPYP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the gene encoding HPYP. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

The polynucleotide sequence encoding HPYP may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second

round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186). The primers may be designed using OLIGO® 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and may be is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In

particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HPYP, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of HPYP in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express HPYP.

As will be understood by those of skill in the art, it may be advantageous to produce HPYP-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the HPYP coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequence. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, to change codon preference, to produce splice variants, or other mutations, and so forth.

In another embodiment of the invention, a natural, modified, or recombinant polynucleotide encoding HPYP may be ligated to a heterologous sequence to encode a fusion

protein. For example, to screen peptide libraries for inhibitors of HPYP activity, it may be useful to encode a chimeric HPYP protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a HPYP encoding sequence and the heterologous protein sequence, so that HPYP may be
5 cleaved and purified away from the heterologous moiety.

In another embodiment, the coding sequence of HPYP may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to
10 synthesize the HPYP amino acid sequence, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high
15 performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of HPYP, or any part thereof, may be altered during direct synthesis and/or combined using chemical
20 methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HPYP, the nucleotide sequence encoding HPYP or functional equivalents, may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the
25 inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing a HPYP coding sequence and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in
30 Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor

Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express a HPYP coding sequence. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and ptrp-lac hybrids, and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HPYP, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HPYP. For example, when large quantities of HPYP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HPYP may be ligated into the vector in frame with sequences for the

amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression of a sequence encoding HPYP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105).

These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express HPYP. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequence encoding HPYP may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of HPYP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein.

The recombinant viruses may then be used to infect, for example, S. frugiperda cells or

Trichoplusia larvae in which HPYP may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a sequence encoding HPYP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HPYP in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of a sequence encoding HPYP. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HPYP, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing

of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HPYP may be transformed using expression vectors which may contain viral origins of replication and/or endogenous
5 expression elements and a selectable marker gene on the same or separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells
10 may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or apt⁻ cells, respectively. Also,
15 antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra).
20 Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely
25 used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example,
30 if the sequence encoding HPYP is inserted within a marker gene sequence, recombinant cells

containing sequences encoding HPYP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HPYP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the coding sequence for HPYP and express HPYP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the polynucleotide sequence encoding HPYP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding HPYP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the HPYP-encoding sequence to detect transformants containing DNA or RNA encoding HPYP. As used herein

"oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression of HPYP, using either polyclonal or monoclonal antibodies specific for the protein are known in the art.

Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HPYP is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983) J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HPYP include oligolabeling, nick translation, end-labeling or PCR amplification

using a labeled nucleotide. Alternatively, the sequence encoding HPYP, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides.

5 These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

10 Host cells transformed with a nucleotide sequence encoding HPYP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HPYP may be designed
15 to contain signal sequences which direct secretion of HPYP through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding HPYP to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow
20 purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and HPYP may be used to facilitate purification. One such
25 expression vector provides for expression of a fusion protein containing HPYP and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site provides a means for purifying HPYP from the fusion protein. A
30 discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993;

DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of HPYP may be produced by direct peptide synthesis using solid-phase techniques (cf Stewart et al. (1969) Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA; Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HPYP may be chemically synthesized separately and combined using chemical methods to produce the full length molecule

THERAPEUTIC APPLICATIONS

In another embodiment of the invention, HPYP or fragments thereof may be used for therapeutic purposes.

Since cGMP and cAMP are important elements of cell signaling pathways in virtually all cells and tissues, the control of specific PPase activity in specific cell types could provide a mechanism for controlling cell signaling and be useful in the treatment of diseases and conditions associated with uncontrolled cell signaling and cell proliferation such as inflammatory diseases and cancer.

Based on the chemical and structural homology among HPYP (SEQ ID NO:1), other pyrophosphatases and northern analysis (Fig.5) which shows that approximately 50% of the libraries containing HPYP transcripts are associated with either cancer or immune response, expression of HPYP is believed to function in cancer, particularly cancers of the colon, prostate, brain, and pancreas, and in inflammatory disease. In addition, the known function of PPases in promoting cell metabolic reactions and cell growth suggest that HPYP may be useful in promoting cell and tissue regeneration.

Therefore, in one embodiment of the invention, HPYP, a fragment or derivative thereof, a vector expressing HPYP, a fragment or derivative thereof, may be used to trigger the regeneration of cells, tissues, or organs which were previously differentiated or not easily regenerated. This would be especially useful in, but is not limited to, the regeneration or transplantation and development of nerve, pancreatic, bone marrow, prostate tissue, and

would involve supplying various natural molecules, such as HPYP, in drug regimes that allow cell division and differentiation to occur. Small amounts of new functional tissue have the capacity to greatly improve the quality of life for victims of accidents or degenerative hereditary diseases.

5 Since expression of HPYP is highly correlated with cancer (Fig. 5), vectors expressing antisense, and antagonists or inhibitors of the protein may be used inhibit the expression or activity of HPYP as a means of suppressing tumor cell growth. Control of HPYP activity as a novel approach to cancer treatment may be especially useful in combination therapy with other chemotherapeutic agents. Such combinations of therapeutic agents having different
10 cellular mechanisms of action often have synergistic effects allowing the use of lower effective doses of each agent and lessening side effects.

 In another embodiment, vectors expressing antisense, and antagonists or inhibitors of the protein may be used to suppress the excessive proliferation of inflammatory cells which cause damage in immunological diseases. Such immune diseases include, but are not limited
15 to, anemias, asthma, systemic lupus, and myasthenia gravis, diabetes mellitus, osteoporosis, glomerulonephritis; rheumatoid and osteoarthritis; and scleroderma.

 In another embodiment, antagonists which block or modulate the effect of HPYP may be used in those situations where such inhibition is therapeutically desirable. Such antagonists or inhibitors may be produced using methods which are generally known in the
20 art, and include particularly the use of purified HPYP to produce antibodies or to screen libraries of pharmaceutical agents for those which specifically bind HPYP. For example, in one aspect, antibodies which are specific for HPYP may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HPYP.

25 The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

30 For the production of antibodies, various hosts including goats, rabbits, rats, mice,

humans, and others, may be immunized by injection with HPYP or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to HPYP have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HPYP amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to HPYP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Koehler et al. (1975) Nature 256:495-497; Kosbor et al. (1983) Immunol. Today 4:72; Cote et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc., New York, NY, pp. 77-96).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger et al. (1984) Nature 312:604-608; Takeda et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HPYP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for HPYP may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse et al. (1989) Science 256:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between HPYP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HPYP epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding HPYP, or any fragment thereof, or antisense sequences, may be used for therapeutic purposes. In one aspect, antisense to the polynucleotide encoding HPYP may be used in situations in which it would be desirable to block the synthesis of the protein. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HPYP. Thus, antisense sequences may be used to modulate HPYP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HPYP.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in

the art can be used to construct recombinant vectors which will express antisense polynucleotides of the gene encoding HPYP. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding HPYP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes HPYP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding HPYP, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HPYP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of

between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HPYP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a

pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HPYP, antibodies to HPYP, mimetics, agonists, antagonists, or inhibitors of HPYP. The compositions may be administered alone or in combination with at least one
5 other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by
10 any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which
15 facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using
20 pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of
25 active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium
30 carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin

and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HPYP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HPYP or fragments thereof, antibodies of HPYP, agonists, antagonists or inhibitors of HPYP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of

administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HPYP may be used for the diagnosis of conditions or diseases characterized by expression of HPYP, or in assays to monitor patients being treated with HPYP, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HPYP include methods which utilize the antibody and a label to detect HPYP in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring HPYP are known in the art and provide a basis for diagnosing altered or abnormal levels of HPYP expression. Normal or standard values for HPYP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with

antibody to HPYP under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of HPYP expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HPYP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HPYP may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of HPYP, and to monitor regulation of HPYP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HPYP or closely related molecules, may be used to identify nucleic acid sequences which encode HPYP. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding HPYP, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the HPYP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring HPYP.

Means for producing specific hybridization probes for DNAs encoding HPYP include the cloning of nucleic acid sequences encoding HPYP or HPYP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes

may be labeled by a variety of reporter groups, for example, radionuclides such as ^{32}P or ^{35}S , or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HPYP may be used for the diagnosis of conditions or diseases which are associated with expression of HPYP. Examples of such conditions or diseases include cancers of the colon, prostate, brain, and pancreas and inflammatory diseases such as anemias, asthma, systemic lupus, and myasthenia gravis, diabetes mellitus, osteoporosis, glomerulonephritis; rheumatoid and osteoarthritis; and scleroderma. The polynucleotide sequences encoding HPYP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered HPYP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HPYP may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequence encoding HPYP may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequence has hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding HPYP in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of HPYP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes HPYP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount

of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

5 Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

10 With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the
15 development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides encoding HPYP may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'→3') and another with antisense (3'←5'), employed
20 under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HPYP include
25 radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and
30 a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequence which encodes HPYP may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of the gene encoding HPYP on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HPYP, its catalytic or immunogenic

fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HPYP and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to HPYP large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HPYP, or fragments thereof, and washed. Bound HPYP is then detected by methods well known in the art. Purified HPYP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HPYP specifically compete with a test compound for binding HPYP. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HPYP.

In additional embodiments, the nucleotide sequences which encode HPYP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I LUNGNOTO4 cDNA Library Construction

The LUNGNOTO4 cDNA library was constructed from lung tissue obtained from a 2-year-old male (specimen #RU95-09-0664; International Institute of Advanced Medicine, Exton PA) who died of anoxia. The cells were lysed using a Brinkmann Homogenizer

Polytron PT-3000 (Brinkmann Instruments, Westbury NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with phenol chloroform pH 4.0, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water and DNase treated at 37°C. The RNA was re-extracted with phenol chloroform pH 8.0 and precipitated using sodium acetate and ethanol as before. The mRNA was then isolated using the Qiagen Oligotex kit (QIAGEN Inc, Chatsworth, CA) and used to construct the cDNA library.

The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013; Gibco/BRL). cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5a™ competent cells (Cat. #18258-012; Gibco/BRL).

II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173; QIAGEN Inc.). This kit enables the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711, LIFE TECHNOLOGIES™, Gaithersburg, MD) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) the cultures were incubated for 19 hours after the wells were inoculated and then lysed with 0.3 ml of lysis buffer; 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a Beckman 96-well block for storage.

The cDNAs were sequenced by the method of Sanger F and AR Coulson (1975; J Mol Biol 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

5 Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 sequence analysis system. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles, CA) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a
10 combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches. Smith-Waterman alignments were used to display the results of the homology search.

15 Peptide and protein sequence homologies were ascertained using the INHERIT- 670 sequence analysis system using the methods similar to those used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant
20 homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul et al. (1990) J. Mol. Biol. 215:403-410), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the
25 alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold
30 or cutoff score set by the user. The BLAST approach is to look for HSPs between a query

sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HPYP occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of HPYP-Encoding Polynucleotides to Full Length or to Recover Regulatory Sequences

Full length HPYP-encoding nucleic acid sequence (SEQ ID NO:2) is used to design oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
Step 3	68° C for 6 min
Step 4	94° C for 15 sec
Step 5	65° C for 1 min
Step 6	68° C for 7 min
Step 7	Repeat step 4-6 for 15 additional cycles
Step 8	94° C for 15 sec
Step 9	65° C for 1 min
Step 10	68° C for 7:15 min

Step 11	Repeat step 8-10 for 12 cycles
Step 12	72° C for 8 min
Step 13	4° C (and holding)

5 A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products are selected and removed from the gel. Further purification involves using a commercial gel extraction method such as QIAQuick™ (QIAGEN Inc.). After recovery of the DNA, Klenow
10 enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells
15 (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an
20 appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers
25 used for the extension reaction are added to each well. Amplification is performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
30 Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec

Step 7 4° C (and holding)

Aliquots of the PCR reactions are run on agarose gels together with molecular weight markers. The sizes of the PCR products are compared to the original partial cDNAs, and
5 appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about
10 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 µCi of [γ -³²P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with
15 Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A portion containing 10⁷ counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and
20 transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics,
25 Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Antisense Molecules

Antisense molecules to the HPYP-encoding sequence, or any part thereof, is used to inhibit in vivo or in vitro expression of naturally occurring HPYP. Although use of antisense
30 oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the

same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of HPYP, as shown in Fig. 1, is used to inhibit expression of naturally occurring HPYP. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Fig. 1 and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an HPYP-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or 5' coding sequence of the polypeptide as shown in Fig. 1.

VIII Expression of HPYP

Expression of HPYP is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express HPYP in *E. coli*. upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HPYP into the bacterial growth media which can be used directly in the following assay for activity.

IX Demonstration of HPYP Activity

HPYP activity is measured by the hydrolysis of ^{32}P -labeled PPi and quantitation of the recovered radioactivity using a gamma radioisotope counter. HPYP is incubated together with PPi in a PPase buffer containing 1-3 mM MgCl_2 and incubated at 37°C for 10 minutes. PPi and Pi are then separated by polyethyleneimine cellulose thin layer chromatography in 1M KH_2PO_4 and the Pi fraction is isolated and counted. The radioactivity recovered is

proportional to the enzyme activity.

X Production of HPYP Specific Antibodies

HPYP that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring HPYP Using Specific Antibodies

Naturally occurring or recombinant HPYP is substantially purified by immunoaffinity chromatography using antibodies specific for HPYP. An immunoaffinity column is constructed by covalently coupling HPYP antibody to an activated chromatographic resin, such as CnBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HPYP is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HPYP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HPYP binding (eg, a buffer of pH 2-3 or a high concentration of a

chaotrope, such as urea or thiocyanate ion), and HPYP is collected.

XII Identification of Molecules Which Interact with HPYP

5 HPYP or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HPYP, washed and any wells with labeled HPYP complex are assayed. Data obtained using different concentrations of HPYP are used to calculate values for the number, affinity, and association of HPYP with the
10 candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection
15 with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Hawkins, Phillip R.
Hillman, Jennifer L.
- (ii) TITLE OF THE INVENTION: A NOVEL HUMAN PYROPHOSPHATASE
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ Version 1.5
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Filed Herewith
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0148 US
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 855-0555
 - (B) TELEFAX: (415) 845-4166

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 289 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY:
 - (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met	Ser	Gly	Phe	Ser	Thr	Glu	Glu	Arg	Ala	Ala	Pro	Phe	Ser	Leu	Glu
1				5					10					15	
Tyr	Arg	Val	Phe	Leu	Lys	Asn	Glu	Lys	Gly	Gln	Tyr	Ile	Ser	Pro	Phe
			20					25					30		
His	Asp	Ile	Pro	Ile	Tyr	Ala	Asp	Lys	Asp	Val	Phe	His	Met	Val	Val
		35					40				45				
Glu	Val	Pro	Arg	Trp	Ser	Asn	Ala	Lys	Met	Glu	Ile	Ala	Thr	Lys	Asp
	50					55					60				

Pro Leu Asn Pro Ile Lys Gln Asp Val Lys Lys Gly Lys Leu Arg Tyr
65 70 75 80
Val Ala Asn Leu Phe Pro Tyr Lys Gly Tyr Ile Trp Asn Tyr Gly Ala
85 90 95
Ile Pro Gln Thr Trp Glu Asp Pro Gly His Asn Asp Lys His Thr Gly
100 105 110
Cys Cys Gly Asp Asn Asp Pro Ile Asp Val Cys Glu Ile Gly Ser Lys
115 120 125
Val Cys Ala Arg Gly Glu Ile Ile Gly Val Lys Val Leu Gly Ile Leu
130 135 140
Ala Met Ile Asp Glu Gly Glu Thr Asp Trp Lys Val Ile Ala Ile Asn
145 150 155 160
Val Asp Asp Pro Asp Ala Ala Asn Tyr Asn Asp Ile Asn Asp Val Lys
165 170 175
Arg Leu Lys Pro Gly Tyr Leu Glu Ala Thr Val Asp Trp Phe Arg Arg
180 185 190
Tyr Lys Val Pro Asp Gly Lys Pro Glu Asn Glu Phe Ala Phe Asn Ala
195 200 205
Glu Phe Lys Asp Lys Asp Phe Ala Ile Asp Ile Ile Lys Ser Thr His
210 215 220
Asp His Trp Lys Ala Leu Val Thr Lys Lys Thr Asn Gly Lys Gly Ile
225 230 235 240
Ser Cys Met Asn Thr Thr Leu Ser Glu Ser Pro Phe Lys Cys Asp Pro
245 250 255
Asp Ala Ala Arg Ala Ile Val Asp Ala Leu Pro Pro Pro Cys Glu Ser
260 265 270
Ala Cys Thr Val Pro Thr Asp Val Asp Lys Trp Phe His His Gln Lys
275 280 285
Asn

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1275 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vii) IMMEDIATE SOURCE:
(A) LIBRARY:
(B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CAAGAGGTTN	GGGGCTCTCT	CCTTGTCAGT	CGGCGCCGCG	TGCGGGCTGG	TGGCTCTGTG	60
GCAGCGGCGG	CGGCAGGACT	CCGGCACTAT	GAGCGGCTTC	AGCACCGAGG	AGCGCGCCGC	120
GCCCTTCTCC	CTGGAGTACC	GAGTCTTCCT	CAAAAATGAG	AAAGGACAAT	ATATATCTCC	180
ATTTTCATGAT	ATTCCAATTT	ATGCAGATAA	GGATGTGTTT	CACATGGTAG	TTGAAGTACC	240
ACGCTGGTCT	AATGCAAAAA	TGGAGATTGC	TACAAAGGAC	CCTTTAAACC	CTATTAAACA	300
AGATGTGAAA	AAAGGAAAAC	TTCGCTATGT	TGCGAATTTG	TTCCCGTATA	AAGGATATAT	360
CTGGAACAT	GGTGCCATCC	CTCAGACTTG	GGAAGACCCA	GGGCACAATG	ATAAACATAC	420
TGGCTGTTGT	GGTGACAATG	ACCCAATTGA	TGTGTGTGAA	ATTGGAAGCA	AGGTATGTGC	480
AAGAGGTGAA	ATAATTGGCG	TGAAAGTTCT	AGGCATATTG	GCTATGATTG	ACGAAGGGGA	540
AACCGACTGG	AAAGTCATTG	CCATTAATGT	GGATGATCCT	GATGCAGCCA	ATTATAATGA	600
TATCAATGAT	GTCAAACGGC	TGAAACCTGG	CTACTTAGAA	GCTACTGTGG	ACTGGTTTAG	660
AAGGTATAAG	GTTCTTGATG	GAAAACCAGA	AAATGAGTTT	GCGTTTAAATG	CAGAATTTAA	720
AGATAAGGAC	TTTGCCATTG	ATATTATTAA	AAGCACTCAT	GACCATTGGA	AAGCATTAGT	780
GACTAAGAAA	ACGAATGGAA	AAGGAATCAG	TTGCATGAAT	ACAACTTTGT	CTGAGAGCCC	840
CTTCAAGTGT	GATCCTGATG	CTGCCAGAGC	CATTGTGGAT	GCTTTACCAC	CACCCTGTGA	900
ATCTGCCTGC	ACAGTACCAA	CAGACGTGGA	TAAGTGGTTC	CATCACCAGA	AAAACATATG	960
AGATTTCTCT	GGAATACAAG	CTGATATTGC	TACATCGTGT	TCATCTGGAT	GTATTAGAAG	1020
TAAAAGTAGT	AGCTTTTCAA	AGCTTTAAAT	TTGTAGAACT	CATCTAACTA	AAGTAAATTC	1080
TGCTGTGACT	AATCCAATAT	ACTCAGAATG	TTATCCATCT	AAAGCATTTT	TCATATCTCA	1140
ACTAAGATAA	CTTTTAGCAC	ATGCTTAAAT	ATCAAAGCAG	TTGTCATTTG	GAAGTCACTT	1200

GTGAATAGAT GTGCAAGGGG AGCACATATT GGATGTATAT GTTACCATAT GTTAGGAAAT 1260
 AAAATTATTT TGCTG 1275

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 114 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 727225

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Asn	Ile	Phe	Pro	Tyr	Lys	Gly	Tyr	Ile	Trp	Asn	Tyr	Gly	Thr	Leu	Pro
1				5					10					15	
Gln	Thr	Trp	Glu	Asp	Pro	His	Glu	Lys	Asp	Lys	Ser	Thr	Asn	Cys	Phe
			20					25					30		
Gly	Asp	Asn	Asp	Pro	Ile	Asp	Val	Cys	Glu	Ile	Gly	Ser	Lys	Ile	Leu
		35					40					45			
Ser	Cys	Gly	Glu	Val	Ile	His	Val	Lys	Ile	Leu	Gly	Ile	Leu	Ala	Leu
	50					55				60					
Ile	Asp	Glu	Gly	Glu	Thr	Asp	Trp	Lys	Leu	Ile	Ala	Ile	Asn	Ala	Asn
65					70				75					80	
Asp	Pro	Glu	Ala	Ser	Lys	Phe	His	Asp	Ile	Asp	Asp	Val	Lys	Lys	Phe
				85				90					95		
Lys	Pro	Gly	Tyr	Leu	Glu	Ala	Thr	Leu	Asn	Trp	Phe	Arg	Leu	Tyr	Lys
			100					105					110		
Val	Pro														

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 289 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 585322

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Ser	Ser	Phe	Ser	Ser	Glu	Glu	Arg	Ala	Ala	Pro	Phe	Thr	Leu	Glu
1				5					10					15	
Tyr	Arg	Val	Phe	Leu	Lys	Asn	Glu	Lys	Gly	Gln	Tyr	Ile	Ser	Pro	Phe
			20					25					30		
His	Asp	Ile	Pro	Ile	Tyr	Ala	Asp	Lys	Glu	Val	Phe	His	Met	Val	Val
		35					40					45			
Glu	Val	Pro	Arg	Trp	Ser	Asn	Ala	Lys	Met	Glu	Ile	Ala	Thr	Lys	Asp
	50					55				60					
Pro	Leu	Asn	Pro	Ile	Lys	Gln	Asp	Val	Lys	Lys	Gly	Lys	Leu	Arg	Tyr
65					70				75					80	
Val	Ala	Asn	Leu	Phe	Pro	Tyr	Lys	Gly	Tyr	Ile	Trp	Asn	Tyr	Gly	Ala
				85				90					95		
Ile	Pro	Gln	Thr	Trp	Glu	Asp	Pro	Gly	His	Asn	Asp	Lys	His	Thr	Gly
			100					105					110		
Cys	Cys	Gly	Asp	Asn	Asp	Pro	Ile	Asp	Val	Cys	Glu	Ile	Gly	Ser	Lys

```

      115      120      125
Val Cys Ala Arg Gly Glu Ile Ile Arg Val Lys Val Leu Gly Ile Leu
130      135      140
Ala Met Ile Asp Glu Gly Glu Thr Asp Trp Lys Val Ile Ala Ile Asn
145      150      155      160
Val Glu Asp Pro Asp Ala Ala Asn Tyr Asn Asp Ile Asn Asp Val Lys
165      170      175
Arg Leu Lys Pro Gly Tyr Leu Glu Ala Thr Val Asp Trp Phe Arg Arg
180      185      190
Tyr Lys Val Pro Asp Gly Lys Pro Glu Asn Glu Phe Ala Phe Asn Ala
195      200      205
Glu Phe Lys Asp Lys Asn Phe Ala Ile Asp Ile Ile Glu Ser Thr His
210      215      220
Asp Tyr Trp Arg Ala Leu Val Thr Lys Lys Thr Asp Gly Lys Gly Ile
225      230      235      240
Ser Cys Met Asn Thr Thr Val Ser Glu Ser Pro Phe Gln Cys Asp Pro
245      250      255
Asp Ala Ala Lys Ala Ile Val Asp Ala Leu Pro Pro Pro Cys Glu Ser
260      265      270
Ala Cys Thr Ile Pro Thr Asp Val Asp Lys Trp Phe His His Gln Lys
275      280      285
Asn

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 287 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 4199

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Thr Tyr Thr Thr Arg Gln Ile Gly Ala Lys Asn Thr Leu Glu Tyr
1      5      10      15
Lys Val Tyr Ile Glu Lys Asp Gly Lys Pro Val Ser Ala Phe His Asp
20      25      30
Ile Pro Leu Tyr Ala Asp Lys Glu Asn Asn Ile Phe Asn Met Val Val
35      40      45
Glu Ile Pro Arg Trp Thr Asn Ala Lys Leu Glu Ile Thr Lys Glu Glu
50      55      60
Thr Leu Asn Pro Ile Ile Gln Asp Thr Lys Lys Gly Lys Leu Arg Phe
65      70      75      80
Val Arg Asn Cys Phe Pro His His Gly Tyr Ile His Asn Tyr Gly Ala
85      90      95
Phe Pro Gln Thr Trp Glu Asp Pro Asn Val Ser His Pro Glu Thr Lys
100      105      110
Ala Val Gly Asp Asn Asp Pro Ile Asp Val Leu Glu Ile Gly Glu Thr
115      120      125
Ile Ala Tyr Thr Gly Gln Val Lys Gln Val Lys Ala Leu Gly Ile Met
130      135      140
Ala Leu Leu Asp Glu Gly Glu Thr Asp Trp Lys Val Ile Ala Ile Asp
145      150      155      160
Ile Asn Asp Pro Leu Ala Pro Lys Leu Asn Asp Ile Glu Asp Val Glu
165      170      175
Lys Tyr Phe Pro Gly Leu Leu Arg Ala Thr Asn Glu Trp Phe Arg Ile
180      185      190
Tyr Lys Ile Pro Asp Gly Lys Pro Glu Asn Gln Phe Ala Phe Ser Gly
195      200      205
Glu Ala Lys Asn Lys Lys Tyr Ala Leu Asp Ile Ile Lys Glu Thr His
210      215      220

```


PF-0148 US

Asp	Ser	Trp	Lys	Gln	Leu	Ile	Ala	Gly	Lys	Ser	Ser	Asp	Ser	Lys	Gly
225					230				235						240
Ile	Asp	Leu	Thr	Asn	Val	Thr	Leu	Pro	Asp	Thr	Pro	Thr	Tyr	Ser	Lys
				245					250					255	
Ala	Ala	Ser	Asp	Ala	Ile	Pro	Pro	Ala	Ser	Leu	Lys	Ala	Asp	Ala	Pro
			260					265					270		
Ile	Asp	Lys	Ser	Ile	Asp	Lys	Trp	Phe	Phe	Ile	Ser	Gly	Ser	Val	
		275					280					285			

152007 "04251450

What is claimed is:

1. A substantially purified human pyrophosphatase (HPYP) comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.

2. An isolated and purified polynucleotide sequence encoding HPYP of claim 1.

3. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.

4. A hybridization probe comprising the polynucleotide sequence of claim 2.

5. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.

6. A polynucleotide sequence which is complementary to SEQ ID NO:2 or variants thereof.

7. A hybridization probe comprising the polynucleotide sequence of claim 6.

8. An expression vector containing the polynucleotide sequence of claim 2.

9. A host cell containing the vector of claim 8.

10. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 the method comprising the steps of:

a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and

b) recovering the polypeptide from the host cell culture.

11. A purified antibody which binds specifically to the polypeptide of claim 1.

12. A purified agonist which specifically binds to and modulates the activity of the
5 polypeptide of claim 1.

13. A purified antagonist which specifically binds to and modulates the activity of the
polypeptide of claim 1.

10 14. A pharmaceutical composition comprising the purified antagonist of claim 13 in
conjunction with a suitable pharmaceutical carrier.

15 15. A method for treating inflammatory disease comprising administering to a subject in
need of such treatment an effective amount of the pharmaceutical composition of claim 14.

16. A method for treating cancer comprising administering to a subject in need of such
treatment an effective amount of the pharmaceutical composition of claim 14.

20 17. A method for detection of polynucleotides encoding HPYP of claim 1 in a biological
sample comprising the steps of:

a) hybridizing a polynucleotide consisting of SEQ ID NO:2 to nucleic acid material
of a biological sample, thereby forming a hybridization complex; and

b) detecting said hybridization complex, wherein the presence of said complex
correlates with the presence of a polynucleotide encoding HPYP in said biological sample.

25 18. The method of claim 17 wherein before hybridization, the nucleic acid material of
the biological sample is amplified by the polymerase chain reaction.

ABSTRACT OF THE DISCLOSURE

A NOVEL HUMAN PYROPHOSPHATASE

5

The present invention provides a human pyrophosphatase (HPYP) and polynucleotides which identify and encode HPYP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPYP and a method for producing HPYP. The invention also provides for use of HPYP and agonists, antibodies, or antagonists specifically binding HPYP, in the prevention and treatment of cancer and inflammatory diseases. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPYP for the treatment of diseases associated with the expression of HPYP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPYP.

10

15

FIGURE1A

387	ATC CCT CAG ACT TGG GAA GAC CCA GGG CAC AAT GAT AAA CAT ACT GGC TGT TGT	396	405	414	423	432
I P Q T W E D P G H N D K H T G C C						
441	GGT GAC AAT GAC CCA ATT GAT GTG TGT GAA ATT GGA AGC AAG GTA TGT GCA AGA	450	459	468	477	486
G D N D P I D D V C E I G S K V C A R						
495	GGT GAA ATA ATT GGC GTG AAA GTT CTA GGC ATA TTG GCT ATG ATT GAC GAA GGG	504	513	522	531	540
G E I I G V K V L G I L A M I D E G						
549	GAA ACC GAC TGG AAA GTC ATT GCC ATT AAT GTG GAT GAT CCT GAT GCA GCC AAT	558	567	576	585	594
E T D W K V I A I N V D D P D A A N						
603	TAT AAT GAT ATC AAT GAT GTC AAA CGG CTG AAA CCT GGC TAC TTA GAA GCT ACT	612	621	630	639	648
Y N D I N D V K R L K P G Y L E A T						
657	GTG GAC TGG TTT AGA AGG TAT AAG GTT CCT GAT GGA AAA CCA GAA AAT GAG TTT	666	675	684	693	702
V D W F R R Y K V P D G K P E N E F						
711	GCG TTT AAT GCA GAA TTT AAA GAT AAG GAC TTT GCC ATT GAT ATT ATT AAA AGC	720	729	738	747	756
A F N A E F K D K D F A I D I I K S						

FIGURE1B

765	774	783	792	801	810
ACT CAT GAC CAT TGG AAA GCA TTA GTG ACT AAG AAA ACG AAT GGA AAA GGA ATC					
T H D H H W K A L V T K K T N G K G I					
819	828	837	846	855	864
AGT TGC ATG AAT ACA ACT TTG TCT GAG AGC CCC TTC AAG TGT GAT CCT GAT GCT					
S C M N T T L S E S P F K C D P D A					
873	882	891	900	909	918
GCC AGA GCC ATT GTG GAT GCT TTA CCA CCA CCC TGT GAA TCT GCC TGC ACA GTA					
A R A I V D A L P P P C E S A C T V					
927	936	945	954	963	972
CCA ACA GAC GTG GAT AAG TGG TTC CAT CAC CAG AAA AAC TAA TGA GAT TTC TCT					
P T D V D K W F H H Q K N					
981	990	999	1008	1017	1026
GGA ATA CAA GCT GAT ATT GCT ACA TCG TGT TGT TCA TCT GGA TGT ATT AGA AGT AAA					
1035	1044	1053	1062	1071	1080
AGT AGT AGC TTT TCA AAG CTT TAA ATT TGT AGA ACT CAT CTA ACT AAA GTA AAT					

FIGURE 1C

1089	1098	1107	1116	1125	1134
TCT GCT GTG ACT AAT CCA ATA TAC TCA GAA TGT TAT CCA TCT AAA GCA TTT TTC					
1143	1152	1161	1170	1179	1188
ATA TCT CAA CTA AGA TAA CTT TTA GCA CAT GCT TAA ATA TCA AAG CAG TTG TCA					
1197	1206	1215	1224	1233	1242
TTT GGA AGT CAC TTG TGA ATA GAT GTG CAA GGG GAG CAC ATA TTG GAT GTA TAT					
1251	1260	1269			
GTT ACC ATA TGT TAG GAA ATA AAA TTA TTT TGC TG 3'					

FIGURE 1D

1	M	S	G	F	S	T	E	E	R	A	A	P	F	S	L	E	Y	R	V	F	L	K	N	E	K	G	Q	Y	I	S	P	F	H	D	I	P	I	Y	A	D	HPYP
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	g727225		
1	M	S	S	F	S	E	E	R	A	A	P	F	T	L	E	Y	R	V	F	L	K	N	E	K	G	Q	Y	I	S	P	F	H	D	I	P	I	Y	A	D	g585322	
1	M	T	-	Y	T	R	Q	I	G	A	K	N	T	L	E	Y	K	V	Y	I	E	K	D	-	G	K	P	V	S	A	F	H	D	I	P	L	Y	A	D	g4199	
41	K	D	-	-	V	F	H	M	V	V	E	V	P	R	W	S	N	A	K	M	E	I	A	T	K	D	P	L	N	P	I	K	Q	D	V	K	K	G	K	L	HPYP
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	g727225		
41	K	E	-	-	V	F	H	M	V	V	E	V	P	R	W	S	N	A	K	M	E	I	A	T	K	D	P	L	N	P	I	K	Q	D	V	K	K	G	K	L	g585322
39	K	E	N	N	I	F	N	M	V	V	E	I	P	R	W	T	N	A	K	L	E	I	T	K	E	E	T	L	N	P	I	I	Q	D	T	K	K	G	K	L	g4199
79	R	Y	V	A	N	L	F	P	Y	K	G	Y	I	W	N	Y	G	A	I	P	Q	T	W	E	D	P	G	H	N	D	K	H	T	G	C	C	G	D	N	D	HPYP
1	-	-	-	-	N	I	F	P	Y	K	G	Y	I	W	N	Y	G	T	L	P	Q	T	W	E	D	P	H	E	K	D	K	S	T	N	C	F	G	D	N	D	g727225
79	R	Y	V	A	N	L	F	P	Y	K	G	Y	I	W	N	Y	G	A	I	P	Q	T	W	E	D	P	G	H	N	D	K	H	T	G	C	C	G	D	N	D	g585322
79	R	F	V	R	N	C	F	P	H	H	G	Y	I	H	N	Y	G	A	F	P	Q	T	W	E	D	P	N	V	S	H	P	E	T	K	A	V	G	D	N	D	g4199
119	P	I	D	V	C	E	I	G	S	K	V	C	A	R	G	E	I	I	G	V	K	V	L	G	I	L	A	M	I	D	E	G	E	T	D	W	K	V	I	A	HPYP
37	P	I	D	V	C	E	I	G	S	K	I	L	S	C	G	E	V	I	H	V	K	I	L	G	I	L	A	L	I	D	E	G	E	T	D	W	K	L	I	A	g727225
119	P	I	D	V	C	E	I	G	S	K	V	C	A	R	G	E	I	I	R	V	K	V	L	G	I	L	A	M	I	D	E	G	E	T	D	W	K	V	I	A	g585322
119	P	I	D	V	L	E	I	G	E	T	I	A	Y	T	G	Q	V	K	Q	V	K	A	L	G	I	M	A	L	L	D	E	G	E	T	D	W	K	V	I	A	g4199

FIGURE 2A

159	I	N	V	D	D	P	D	A	A	N	D	I	N	D	V	K	R	L	K	P	G	Y	L	E	A	T	V	D	W	F	R	R	Y	K	V	P	D	G	HPYP													
77	I	N	A	N	D	P	E	A	S	K	F	H	D	I	D	V	K	K	F	K	P	G	Y	L	E	A	T	L	N	W	F	R	L	Y	K	V	P	g727225														
159	I	N	V	E	D	P	D	A	A	N	D	I	N	D	V	K	R	L	K	P	G	Y	L	E	A	T	V	D	W	F	R	R	Y	K	V	P	D	G	g585322													
159	I	D	I	N	D	P	L	A	P	K	L	N	D	I	E	D	V	E	K	Y	F	P	G	L	L	R	A	T	N	E	W	F	R	I	Y	K	I	P	D	G	g4199											
199	K	P	E	N	E	F	A	F	N	A	E	F	K	D	K	D	F	A	I	D	I	I	K	S	T	H	D	H	W	K	A	L	V	T	-	K	K	T	N	G	HPYP											
114																																																				
199	K	P	E	N	E	F	A	F	N	A	E	F	K	D	K	N	F	A	I	D	I	I	E	S	T	H	D	Y	W	R	A	L	V	T	-	K	K	T	D	G	g727225											
199	K	P	E	N	Q	F	A	F	S	G	E	A	K	N	K	K	Y	A	L	D	I	I	K	E	T	H	D	S	W	K	Q	L	I	A	G	K	S	S	D	S	g585322											
238	K	G	I	S	C	M	N	T	T	L	S	E	S	P	F	K	C	D	P	D	A	A	R	A	I	V	D	A	L	P	P	P	C	-	E	S	A	C	T	V	HPYP											
114																																																				
238	K	G	I	S	C	M	N	T	T	V	S	E	S	P	F	Q	C	D	P	D	A	A	K	A	I	V	D	A	L	P	P	P	C	-	E	S	A	C	T	I	g727225											
239	K	G	I	D	L	T	N	V	T	L	P	D	T	P	-	-	-	-	-	-	-	-	T	Y	S	K	A	A	S	D	A	I	P	P	A	S	L	K	A	D	A	P	I	g585322								
277	P	T	D	V	D	K	W	F	H	H	Q	K	N																																							
114																																																				
277	P	T	D	V	D	K	W	F	H	H	Q	K	N																																							
274	D	K	S	I	D	K	W	F	F	I	S	G	S	V																																						

FIGURE 2B

66B00T" 0155T160




FIGURE 3




FIGURE 4

Library	Lib Description	Abun	Pct Abun
AMLENOT01	AML blast cells, blast crisis, 58 F	1	0.1049
THYRNOT01	thyroid, 64 F	3	0.0683
TBLVNOT01	T-B lymphoblast cell line, leukemia	2	0.0651
COLNTUT03	colon tumor, 62 M, match to COLNNOT16	2	0.0543
U937NOT01	U937 monocyte cell line, 37 M	1	0.0495
TESTNOT01	testis, 37 M	1	0.0469
HNT2AGT01	hNT-2 cell line, post-mitotic neurons	2	0.0380
PROSTUT03	prostate tumor, 67 M, match to PROSNOT05	1	0.0351
LVENNOT03	heart, left ventricle, 31 M	1	0.0336
BRSTNOT03	breast, 54 F, match to BRSTTUT02	2	0.0293
PANCNOT07	pancreas, fetal M	1	0.0286
BEPINON01	bronchial epithelium, primary cell line, 54 M, NORM	1	0.0273
PANCNUT01	pancreatic tumor, 65 F, match to PANCNOT08	1	0.0257
MENITUT03	brain tumor, benign meningioma, 35 F	1	0.0249
TMLR3DT01	lymphocytes (non-adher PBMC), M, 96-hr MLR	1	0.0228
COLNTUT02	colon tumor, 75 M, match to COLNNOT01	1	0.0220
SYNORAB01	synovium, hip, rheumatoid, 68 F	1	0.0194
LUNGNOT04	lung, 2 M	1	0.0182
SYNORAT04	synovium, wrist, rheumatoid, 62 F	1	0.0173
NGANNOT01	ganglioneuroma, 9 M	1	0.0155
BRSTNOT05	breast, 58 F, match to BRSTTUT03	1	0.0154

FIGURE 5

**DECLARATION AND POWER OF ATTORNEY FOR
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

A NOVEL HUMAN PYROPHOSPHATASE

the specification of which:

 is attached hereto.

 X was filed on October 31, 1996, as application Serial No. 08/741,437 and if this box contains an X , was amended on _____.

 was filed as Patent Cooperation Treaty international application No. _____ on _____, 19____, if this box contains an X , was amended on under Patent Cooperation Treaty Article 19 on _____19__, and if this box contains an X , was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application	Status (Pending, Abandoned, Patented)
Serial No. _____ Filed _____	

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749
Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ.
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 415-855-0555 FAX: 415-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

***IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Sole Inventor or

First Joint Inventor:

Full name:

PHILLIP R. HAWKINS

Signature:

Phillip R. Hawkins

Date:

6 January 1996 ^{2nd}

Citizenship:

United States of America

Residence:

Mountain View, California

P.O. Address:

750 N. Shoreline Boulevard, #96
Mountain View, California, 94034

Second Joint Inventor:

Full name:

JENNIFER L. HILLMAN

Signature:

Jennifer L. Hillman

Date:

Jan 2 1996 ^{1st}

Citizenship:

United States of America

Residence:

San Jose, California

P.O. Address:

467 N. Third Steet, #3
San Jose, California, 95112

65007-0434

I hereby certify that this correspondence is being deposited with the United States
Postal Service as first class mail in an envelope addressed to: Box Issue Fee, Assistant Commissioner
for Patents, Washington, D.C. 20231 on October 6, 1999
By: Nancy L. Glynn
Printed: Nancy L. Glynn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: NOVEL HUMAN PYROPHOSPHATASE

Serial No.: 09/134,593

Filing Date: August 13, 1998

Examiner: E. Slobodyansky

Group Art Unit: 1652

Assistant Commissioner for Patents
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3174 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8437, Frame 0115, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Narinder S. Banait
Adam Warwick Bell
Lucy J. Billings
Michael C. Cerrone
Diana Hamlet-Cox
Colette C. Muenzen
Lynn E. Murry

Reg. No. 43,482
Reg. No. 43,490
Reg. No. 36,749
Reg. No. 39,132
Reg. No. 33,302
Reg. No. 39,784
Reg. No. 42,918

Danielle M. Pasqualone
Susan K. Sather
David G. Streeter

Reg. No. 43,847
Reg. No. 44,316
Reg. No. 43,168

Please direct all correspondence to:

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Ph.D.,
Incyte Pharmaceuticals, Inc., Phone: (650) 845-4639 Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the
assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that
these statements are made with the knowledge that willful false statements, and the like so made,
are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United
States Code, and that such willful false statements may jeopardize the validity of the application
or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: October 5, 1999

By: Lee Bendekgey
Lee Bendekgey
VP, General Counsel/Corporate Secretary

"Express Mail" mailing label number EL315813786 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on October 8, 1999

By: Nancy Ramos

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: A NOVEL HUMAN PYROPHOSPHATASE

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Official Draftsman

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figure(s) 1A, 1B, 1C, 1D, 2A, 2B, 3, 4, and 5, as nine (9) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings. Applicants note that the number of sheets of drawings has increased to accomodate the Draftspersons objections. The new formal drawings are identical to those originally filed. No new matter has been added.


Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 08 October 1999



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

6508454166